Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Personalis ( (PSNL) ) is now available.
On July 8, 2025, Personalis, Inc. and Tempus AI, Inc. amended their existing agreement to include colorectal cancer as a new indication for the NeXT Personal® test, alongside breast cancer, lung cancer, and immuno-oncology monitoring. The amendment extends the exclusivity period for marketing the test and modifies certain standstill restrictions, potentially strengthening Personalis’ market position in cancer diagnostics.
The most recent analyst rating on (PSNL) stock is a Buy with a $7.25 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.
Spark’s Take on PSNL Stock
According to Spark, TipRanks’ AI Analyst, PSNL is a Neutral.
The overall stock score of 59.8 reflects a company with strong positive momentum in its technical indicators and promising growth prospects as outlined in the earnings call. However, significant challenges in financial performance and valuation are evident, with ongoing losses and a negative P/E ratio. The positive sentiment from the earnings call boosts the score slightly, but financial health remains a critical concern.
To see Spark’s full report on PSNL stock, click here.
More about Personalis
Personalis, Inc. operates in the biotechnology industry, focusing on advanced genomic testing services. The company’s primary product, NeXT Personal®, is an ultra-sensitive tumor-informed minimal residual disease test, which is used for monitoring various types of cancer.
Average Trading Volume: 1,050,934
Technical Sentiment Signal: Buy
Current Market Cap: $590M
For detailed information about PSNL stock, go to TipRanks’ Stock Analysis page.